Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database
Nusayba A. Bagegni, Tao Yu, Foluso O. Ademuyiwa
PLoS ONE (2019) Vol. 14, Iss. 9, pp. e0222358-e0222358
Open Access | Times Cited: 44

Showing 26-50 of 44 citing articles:

Platinum-Based Chemotherapy and Immunotherapy in Early Triple-Negative Breast Cancer: A Meta-Analysis and Indirect Treatment Comparison
Qin He, Yicheng Peng, Jie Sun, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 7
Changing the role of pCR in breast cancer treatment - an unjustifiable interpretation of a good prognostic factor as a “factor for a good prognosis“
Nebojša Ivanović, Dragana Bjelica, Barbara Loboda, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 2
N-acetylcysteine improves the inhibitory effect of Quercetin-rich onion extract on HT-29 and HCT-116 colorectal cancer migration and invasion through iNOS suppression
Rataya Tanomrat, Chonnapat Naktubtim, Parichaya Aimvijarn, et al.
International Journal of Medical Sciences (2023) Vol. 20, Iss. 9, pp. 1123-1134
Open Access | Times Cited: 2
Value of 18F-FDG PET/CT for predicting axillary pathologic complete response following neoadjuvant systemic therapy in breast cancer patients: emphasis on breast cancer subtype
Cornelis M. de Mooij, Cristina Mitea, Felix M. Mottaghy, et al.
EJNMMI Research (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 5
Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis in 36480 cases.
Lin-Yu Xia, Qing-Lin Hu, Jing Zhang, et al.
Research Square (Research Square) (2020)
Open Access | Times Cited: 5
PITX2 DNA-Methylation: Predictive versus Prognostic Value for Anthracycline-Based Chemotherapy in Triple-Negative Breast Cancer Patients
Rudolf Napieralski, Gabriele Schricker, Gert Auer, et al.
Breast Care (2020) Vol. 16, Iss. 5, pp. 523-531
Open Access | Times Cited: 4
Impact of Race and Health Insurance Status on Response to Neoadjuvant Chemotherapy for Breast Cancer Patients
Yvonne Ho, A.A. Harris, Michael Wesolowski, et al.
Cureus (2021)
Open Access | Times Cited: 4
Real-world data on adjuvant capecitabine after standard neoadjuvant chemotherapy for triple negative breast cancer
Maria Fernanda Império Pereira, Isabela Buzatto, Hélio Angotti Neto, et al.
Revista Brasileira Ginecologia e Obstetrícia (2024) Vol. 46
Open Access
Assessing Clinicopathological Features and Prognosis of Triple-Negative Breast Cancer Patients: A Single-Center Study in Turkey
Saliha Karagöz Eren, Alaettin Arslan, Ebru Akay, et al.
Archives of Breast Cancer (2021), pp. 297-304
Open Access | Times Cited: 3
Wohin entwickelt sich die operative Senologie?
Markus Hahn, Bernd Gerber
Der Gynäkologe (2020) Vol. 53, Iss. 5, pp. 300-308
Closed Access | Times Cited: 1
Liver x receptor alpha drives chemoresistance in response to side-chain hydroxycholesterols in triple negative breast cancer
Samantha A. Hutchinson, Alex Websdale, Giorgia Cioccoloni, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 1
Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36480 cases. 
Lin-Yu Xia, Qing-Lin Hu, Jing Zhang, et al.
Research Square (Research Square) (2020)
Open Access | Times Cited: 1
Triple negative breast cancer and reconstruction: Predictors of recurrence, complications, and mortality
Olutayo Sogunro, Adaah A. Sayyed, Nathan Aminpour, et al.
Breast Disease (2022) Vol. 41, Iss. 1, pp. 343-350
Closed Access | Times Cited: 1
The Effect of Neoadjuvant vs Adjuvant Chemotherapy on Final Outcome of Patients with Triple Negative Breast Cancer
Najmeh Dabbagh, Hooman Riazi, Maryam Khayamzadeh, et al.
Medical Journal of the Islamic Republic of Iran (2022)
Open Access | Times Cited: 1
Up to your NEK2 in CIN
Darcie D. Seachrist, Lindsey J. Anstine, Ruth A. Keri
Oncotarget (2021) Vol. 12, Iss. 8, pp. 723-725
Open Access | Times Cited: 1
Real‑world data indicated that neoadjuvant chemotherapy alone was associated with a higher risk of tumor recurrence in high‑risk breast cancer subgroup patients
Zhensheng Li, Yue Li, Yunjiang Liu, et al.
Oncology Letters (2023) Vol. 25, Iss. 5
Open Access
Predictive Factors for Relapse in Triple-negative Breast Cancer Patients Without Pathologic Complete Response After Neoadjuvant Chemotherapy
Angela Toss, Marta Venturelli, Monica Civallero, et al.
Research Square (Research Square) (2022)
Open Access
Patterns of Relapse Related to High Expression of Ki-67 After Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Ginés Hernández-Cortes, Javier Hornedo, Raquel Murillo, et al.
Journal of Gynecology and Obstetrics (2021) Vol. 9, Iss. 5, pp. 139-139
Open Access
Role of Tumor Subtypes in Response to Neoadjuvant Chemotherapy in Non-metastatic Breast Cancer
Negar Mashoori, Ramesh Omranipour, Abdolali Assarian
Archives of Iranian Medicine (2021) Vol. 24, Iss. 12, pp. 881-886
Open Access
Previous Page - Page 2

Scroll to top